304 related articles for article (PubMed ID: 17385948)
21. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
Reid IR; Maslowski K
Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
[TBL] [Abstract][Full Text] [Related]
22. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
23. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy.
Pane A
Arch Ophthalmol; 2007 Oct; 125(10):1440-1. PubMed ID: 17923566
[No Abstract] [Full Text] [Related]
24. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
[TBL] [Abstract][Full Text] [Related]
25. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
26. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
27. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
Devogelaer JP; Bergmann P; Body JJ; Boutsen Y; Goemaere S; Kaufman JM; Reginster JY; Rozenberg S; Boonen S;
Osteoporos Int; 2008 Aug; 19(8):1109-17. PubMed ID: 18504638
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
[TBL] [Abstract][Full Text] [Related]
29. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
[TBL] [Abstract][Full Text] [Related]
30. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
[TBL] [Abstract][Full Text] [Related]
31. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
Grados D; MartÃnez-Morillo M; Holgado S; Erra A
Med Clin (Barc); 2014 May; 142(10):469-70. PubMed ID: 24120108
[No Abstract] [Full Text] [Related]
32. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.
Buckler H; Fraser W; Hosking D; Ryan W; Maricic MJ; Singer F; Davie M; Fogelman I; Birbara CA; Moses AM; Lyles K; Selby P; Richardson P; Seaman J; Zelenakas K; Siris E
Bone; 1999 May; 24(5 Suppl):81S-85S. PubMed ID: 10321935
[No Abstract] [Full Text] [Related]
33. [Paget's disease of bone: diagnosis and treatment].
Winter EM; Hamdy NA; de Jongh RT; Eekhoff EM; Zillikens MC; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2016; 160():D254. PubMed ID: 27650015
[TBL] [Abstract][Full Text] [Related]
34. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.
Tucci JR
Endocr Pract; 2008; 14(5):607-10. PubMed ID: 18753106
[TBL] [Abstract][Full Text] [Related]
35. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
36. Zoledronate treatment in active Paget's disease.
Chung G; Keen RW
Ann Rheum Dis; 2003 Mar; 62(3):275-6. PubMed ID: 12594123
[No Abstract] [Full Text] [Related]
37. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
Garnero P; Christgau S; Delmas PD
Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
[TBL] [Abstract][Full Text] [Related]
38. Pharmacotherapy of Paget's disease of bone.
Reid IR
Expert Opin Pharmacother; 2012 Apr; 13(5):637-46. PubMed ID: 22339140
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.
Reid IR; Wattie D; Gamble GD; Kalluru R; Cundy T
Calcif Tissue Int; 2017 Mar; 100(3):250-254. PubMed ID: 27866237
[TBL] [Abstract][Full Text] [Related]
40. [Paget's disease and its therapeutic management].
Orcel P; Rousière M
Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
